Key Drivers
- Margin Strength
- Free Cash Flow
- Rich Valuation
AIAI Summary
ALNY now looks more like a cash-generative rare-disease commercial franchise than a speculative RNAi story, with AMVUTTRA driving durable earnings and free cash flow, but the stock still depends on sustained execution in ATTR-CM because valuation is rich and any slowdown could trigger a sharp re-rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Strength
- •Free Cash Flow
- •Rich Valuation
ALNY combines high margins, improving profitability, solid liquidity, and strong free cash flow, but its leverage, accumulated losses, and rich valuation keep the stock fundamentally attractive yet expensive.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •$300 reclaim
- •Stretched rebound
Over the last month, ALNY has shifted from a weak downtrend to a constructive rebound, with higher lows and a hold above $300 improving the setup, but a clean break above $313 is needed to confirm further upside.
Fast rebound from $278.09 to $312.78 signals short-term volatility risk
Sentiment & News
Key News Insights:
- •Amvuttra momentum
- •Pipeline diversification
- •Partnership expansion
Alnylam's June–July news emphasized strong Amvuttra momentum, expanding pipeline/commercial partnerships, and growing optimism as it works to diversify growth beyond its lead product.
Positive, as the updates support continued growth visibility while reducing long-term dependence on a single therapy
Similar Companies in Healthcare
Other companies in the same sector with AI ratings